17 Jul 2024 • Metformin use shows a lower incidence of prostate cancer (PCa) based on aggregated study results (Relative Risk [RR]: 0.82, 95% CI: 0.74–0.91). While its impact on PCa recurrence wasn't statistically significant (RR: 0.97, 95% CI: 0.81–1.15), the drug did not affect PCa mortality (RR: 0.94, 95% CI: 0.81–1.09).

• Subgroup analyses highlighted that cohort studies in Asia and Europe consistently supported metformin's protective benefits against PCa. Moreover, a longer duration of metformin use correlated with stronger protective effects.

These findings suggest a potential new avenue in PCa prevention and management strategies.

Source:Prostate Cancer & Prostatic Diseases| Read full story